TSC2 and lymphangioleiomyomatosis: Only one study (Liu et al., 2019) [21] provided both TSC2 mutation information and corresponding clinical data, and the clinical characteristics of the S-LAM patients in Liu’s study were compared with those in the present study [see Additional file 5_sheet1].